SynthesisPloS one2022
Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- All-cause mortality risk in long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis.Molecular psychiatry · 2025Pooled it
- Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.Schizophrenia bulletin · 2024Pooled it
- Pooled it
- Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST).European psychiatry : the journal of the Association of European Psychiatrists · 2026Trial
- Subjective well-being in early-phase schizophrenia patients using long-acting injectable versus oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST).European psychiatry : the journal of the Association of European Psychiatrists · 2025Trial
- The Role of Long-Acting Injectable Antipsychotics in the Early Treatment of Schizophrenia.CNS drugs · 2026Review
- Development and validation of a clinical prediction model and risk score for 30-day psychiatric readmission in the United Arab Emirates.BMC psychiatry · 2026Article
- Mental health antecedents in first episode of psychosis: impact on prognosis across transitional age.European child & adolescent psychiatry · 2026Article
- Comparison of Typical and Atypical Long-Acting Antipsychotics in a Real-World Sample in terms of Treatment Adherence and Factors Influencing Treatment Choice: A One-Year Follow-Up Study.Noro psikiyatri arsivi · 2026Article
- Article
- Clinical and Demographic Characteristics in Schizophrenia Patients with and without a History of Taking Long-acting Injectable Antipsychotics: A Comparative Cross-sectional Study.Journal of research in pharmacy practice · 2026Article
- Differentiating aspects of oral and long-acting injectable antipsychotic drugs for tailoring the therapy of schizophrenia in clinical practice: a narrative review.International clinical psychopharmacology · 2025Review
- Antipsychotics and other risk factors for mortality among people with schizophrenia during an extreme heat event: a population-based case-control study.Scientific reports · 2025Article
- The knowledge and attitudes of psychiatrists toward antipsychotic long-acting injections in Turkiye.Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi · 2025Article
- Clinical Outcomes in Patients with Schizophrenia Treated with Long-Acting Injectable vs. Oral Antipsychotics: A Naturalistic Study.Healthcare (Basel, Switzerland) · 2025Article
- Long-term outcomes of Aripiprazole long-acting injectable: a 10-year mirror image study of patient acceptability and treatment effectiveness.Schizophrenia (Heidelberg, Germany) · 2025Article
- Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia.Neurology and therapy · 2025Article
- Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report.Clinics and practice · 2025Article
- Investigation on the factors associated with maintenance of paliperidone long-acting injection in the real-world treatment of patients with schizophrenia.Therapeutic advances in psychopharmacology · 2025Article
- Predictors of rehospitalization due to violent behavior in patients with psychotic disorders with a history of violent behavior.Frontiers in psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimLong acting injectable (LAI) antipsychotics are an alternative to oral antipsychotic (OAP) treatment and may be beneficial for patients in the early stages of schizophrenia. This study aims to provide a comprehensive review on the efficacy of first-generation and second-generation LAI antipsychotics in recent-onset, first-episode, and early psychosis patients.
methodsMEDLINE, EMBASE, PsycINFO, and Web of Science Core databases were used to search for studies that used LAIs in early psychosis patients. Studies published up to 06 Jun 2019 were included with no language restrictions applied. Inclusion criteria were a diagnosis of schizophrenia or related disorder, where patients were in their first episode or had a duration of illness ≤5 years.
results33 studies were included: 8 RCTs, 4 post-hoc analyses, 2 case reports, and 19 naturalistic studies. The majority of studies evaluated risperidone LAIs (N = 14) and paliperidone palmitate (N = 10), while the remainder investigated fluphenazine decanoate (N = 3), flupentixol decanoate (N = 2), and aripiprazole (N = 1). Two studies did not specify the LAI formulation used, and one cohort study compared the efficacy of multiple different LAI formulations.
conclusionsWhile the majority of data is based on naturalistic studies investigating risperidone LAIs or paliperidone palmitate, LAIs may be an effective treatment for early psychosis patients in terms of adherence, relapse reduction, and symptom improvements. There is still a need to conduct more high quality RCTs that investigate the efficacy of different LAI formulations in early psychosis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.